Publications by authors named "N Erik I Nyholm"

Article Synopsis
  • The study aimed to determine the most cost-effective sequence of anti-IL17 treatments for moderate-to-severe plaque psoriasis in Italy and Germany over five years.
  • Researchers adapted a treatment model to include real-world data on drug discontinuation rates and specific costs for the four available anti-IL17 biologics, using long-term efficacy measures to evaluate effectiveness.
  • The findings indicated that the best treatment sequence is starting with brodalumab, followed by bimekizumab, ixekizumab, and finally secukinumab, resulting in a total cost-per-responder of €128,200 in Italy and €138,212 in Germany.
View Article and Find Full Text PDF
Article Synopsis
  • * A cost per responder model was created, comparing treatments like brodalumab, ixekizumab, and adalimumab, based on their effectiveness measured through the Psoriasis Area and Severity Index (PASI).
  • * Results indicated brodalumab was the most cost-effective option, showing the lowest costs per PASI100-responder in both countries and outperforming other biologics in the same category as well.
View Article and Find Full Text PDF

Background: Psoriasis contributes to unemployment, work impairment, missed workdays and substantial indirect costs due to lost productivity. Combination Cal/BD foam is the only topical that is approved for long-term maintenance treatment of plaque psoriasis for 52 weeks. This is the first known investigation of the effect of topical psoriasis therapy on productivity.

View Article and Find Full Text PDF

Background: Psoriasis has important physical and psychosocial effects that extend beyond the skin. Understanding the impact of treatment on health-related quality of life (HRQoL) and patient-perceived symptom severity in psoriasis is key to clinical decision-making.

Objectives: This post hoc analysis of the PSO-LONG trial data assessed the impact of long-term proactive or reactive management with fixed-dose combination calcipotriene 50 µg/g and betamethasone dipropionate 0.

View Article and Find Full Text PDF

Background: Proactive management of plaque psoriasis with twice-weekly topical calcipotriol/betamethasone dipropionate (Cal/BD) foam has a demonstrated clinical benefit in preventing disease relapse compared to reactive management, where Cal/BD foam is only given as rescue therapy once-daily for four weeks after relapse. The impact of proactive management with Cal/BD foam on a wider range of clinical responses is not yet known, nor is its potential cost-effectiveness in the healthcare system of Finland.

Methods: This study involved a post-hoc analysis exploring the clinical and patient-reported benefits of proactive versus reactive management with Cal/BD foam observed in the PSO-LONG trial (NCT02899962).

View Article and Find Full Text PDF